Last updated: September 4, 2026
Tesamorelin is a niche but commercially durable HIV medicine marketed in the United States as Egrifta SV by Theratechnologies Inc. Its market is supported by a defined medical need, limited direct competition, and recurring treatment demand. Growth is constrained by the small eligible population, daily injection, safety monitoring, payer controls, and competition from broader metabolic therapies that are not approved for the same indication.
Theratechnologies has expanded Egrifta SV revenue through reformulation, improved dosing convenience, specialty-pharmacy distribution, and focused HIV-market promotion. The principal commercial risk is not immediate biosimilar competition. It is gradual erosion from treatment discontinuation, reimbursement pressure, off-label alternatives, and future generic or 505(b)(2) peptide competition.
What is tesamorelin approved to treat?
Tesamorelin is a synthetic growth hormone-releasing factor analog. The FDA approved Egrifta in 2010 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Egrifta SV, a higher-concentration formulation, was approved in 2018 and replaced the original formulation in U.S. commercial distribution.[1,2]
The current Egrifta SV label provides for once-daily subcutaneous administration after reconstitution. Each vial contains 2 mg of tesamorelin, with a recommended dose of 1.4 mg per day.[1]
| Attribute |
Egrifta SV |
| Active ingredient |
Tesamorelin |
| Product type |
Synthetic peptide analog of growth hormone-releasing factor |
| U.S. indication |
Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy |
| Route |
Subcutaneous injection |
| Recommended dose |
1.4 mg once daily |
| Sponsor and commercializer |
Theratechnologies Inc. |
| FDA approval |
Egrifta, 2010; Egrifta SV, 2018 |
| U.S. market position |
Specialty HIV treatment with no direct FDA-approved competitor for the same indication |
Egrifta SV is not approved for general obesity, cosmetic fat reduction, diabetes, or ordinary weight loss. The label states that treatment should be discontinued if there is no reduction in visceral adipose tissue after 26 weeks.[1]
How large is the tesamorelin market?
The tesamorelin market is a specialty pharmaceutical niche rather than a broad obesity market. Its commercial population consists of HIV-positive adults with excess visceral abdominal fat and sufficient access to diagnosis, specialist care, and reimbursement.
The addressable population is limited by several factors:
- Modern antiretroviral therapy has reduced the prevalence of severe HIV-associated lipodystrophy.
- Not all patients with HIV-associated body-composition changes have excess visceral fat that meets treatment criteria.
- Some patients have contraindications, including active malignancy, pregnancy, disruption of the hypothalamic-pituitary-gonadal axis, or significant glucose intolerance.
- Treatment requires daily injections and ongoing monitoring of insulin-like growth factor 1, glucose, and clinical response.
- Payers commonly require prior authorization and documentation of HIV-associated lipodystrophy.
Tesamorelin therefore operates in a concentrated prescriber market involving HIV specialists, infectious disease physicians, endocrinologists, specialty pharmacies, and case-management services. Patient retention and reimbursement approval are more important than mass-market prescription volume.
What is the financial trajectory of tesamorelin and Theratechnologies?
Theratechnologies reports company-wide revenue from its HIV products rather than presenting tesamorelin as an independent public-company segment. The company’s portfolio has historically included Egrifta SV and Trogarzo, an injectable antiretroviral used for multidrug-resistant HIV.
Public filings show a recovery and expansion in Theratechnologies’ revenue base following the launch of Egrifta SV and the company’s efforts to strengthen commercial execution in the United States.[3-5]
| Fiscal period |
Theratechnologies commercial position |
Tesamorelin implication |
| 2018 |
Egrifta SV launched following FDA approval |
Higher-concentration formulation replaced the original Egrifta product |
| 2019-2021 |
U.S. specialty commercialization expanded |
Prescription continuity and reimbursement became the primary growth drivers |
| 2022-2023 |
Product portfolio revenue increased from the post-pandemic base |
Egrifta SV benefited from targeted HIV-market demand |
| 2024 |
Continued emphasis on commercial execution and cost control |
Tesamorelin remained a core recurring-revenue product |
Egrifta SV is strategically important because it produces recurring product revenue without requiring a broad primary-care sales force. Revenue quality depends on continuing patients, refill persistence, and payer coverage. The product’s sales profile is more similar to a specialty chronic therapy than to a short-course treatment.
What drives tesamorelin revenue growth?
The most important revenue drivers are:
- Patient identification. Many eligible patients are managed for HIV but are not actively screened for visceral adiposity or lipodystrophy.
- Prescriber adoption. Treatment is concentrated among HIV specialists and clinicians familiar with body-composition complications.
- Insurance approval. Prior authorization and appeals can determine whether a prescription converts into revenue.
- Persistence. Patients who remain on therapy generate recurring monthly demand.
- Product convenience. Egrifta SV reduced reconstitution and injection burden relative to the original formulation.
- Commercial access. Specialty pharmacy support, copay assistance, benefits verification, and patient services reduce abandonment.
The growth ceiling remains limited. Tesamorelin cannot directly access the much larger general-obesity market under its current FDA label.
How does tesamorelin compare with GLP-1 drugs and growth hormone?
Tesamorelin competes indirectly with several treatment categories but has few direct substitutes within its approved indication.
| Therapy category |
Primary use |
Competitive relationship with tesamorelin |
| GLP-1 and GIP/GLP-1 drugs |
Diabetes and obesity |
Compete for metabolic-care budgets and patient attention but are not approved specifically for HIV-associated lipodystrophy |
| Recombinant human growth hormone |
Growth hormone deficiency and selected indications |
Mechanistically related but has a different regulatory profile and broader systemic effects |
| Lifestyle intervention |
Weight and metabolic management |
Often used alongside or before pharmacologic treatment |
| Bariatric surgery |
Severe obesity |
Relevant only to a small subset of patients and not a direct substitute for HIV-associated visceral adiposity |
| Compounded peptides |
Off-label or nonapproved use |
Regulatory, quality, and reimbursement risks limit their role in the approved market |
| Tesamorelin |
HIV-associated excess abdominal fat |
Only FDA-approved product specifically directed to this condition |
GLP-1 therapies are the principal emerging commercial pressure. Their strong weight-loss efficacy, expanding reimbursement discussion, and increasing use in metabolic disease may change how physicians and payers evaluate tesamorelin. They do not, however, reproduce tesamorelin’s specific evidence base and label for HIV-associated visceral adipose tissue.
The products also differ pharmacologically. Tesamorelin stimulates endogenous growth hormone release, while GLP-1-based therapies primarily alter appetite, gastric emptying, glucose regulation, and body weight. Tesamorelin’s clinical value is tied to visceral adipose-tissue reduction rather than total body-weight loss.[1,6]
What patents protect tesamorelin and Egrifta SV?
Tesamorelin has a weaker long-term exclusivity profile than a recently launched complex biologic. The active peptide has been known for many years, and the principal commercial protection has historically depended on formulation, manufacturing, regulatory exclusivity, trademarks, know-how, and market execution.
The relevant protection layers are:
- Active-ingredient and peptide-analog patents, many of which are older and may have expired or have limited remaining term.
- Formulation and reconstitution patents associated with Egrifta SV.
- Manufacturing and purification know-how.
- Regulatory exclusivity associated with FDA approval and pediatric obligations, where applicable.
- Trademark protection for Egrifta and Egrifta SV.
- Commercial contracting and specialty-pharmacy infrastructure.
The FDA Orange Book should be used as the operative source for current listed patents and regulatory exclusivity. Egrifta SV does not have the same patent-density profile as leading small-molecule blockbusters with multiple late-expiring composition, formulation, metabolite, and method-of-use patents.[7]
Does tesamorelin have biologic or biosimilar protection?
Tesamorelin is a synthetic peptide drug and should not be analyzed as a conventional monoclonal-antibody biologic. A future competitor would more likely pursue an abbreviated drug application, a 505(b)(2) application, or another peptide-specific regulatory route rather than a traditional biosimilar pathway.
That distinction matters commercially. A tesamorelin competitor may face formulation, device, analytical, clinical, and manufacturing barriers, but the legal framework is different from the biosimilar pathway used for products such as adalimumab, trastuzumab, or pegfilgrastim.
When does tesamorelin lose exclusivity?
Tesamorelin’s practical exclusivity is unlikely to end on a single date. The commercial loss-of-exclusivity risk depends on the surviving patent claims, Orange Book listings, regulatory exclusivity, manufacturing capability, and the timing of an actual abbreviated application.
The original Egrifta approval dates do not create a current broad market monopoly. The more relevant questions are whether Egrifta SV-specific formulation or method patents remain enforceable, whether a competitor can design around them, and whether the FDA accepts an abbreviated application based on the reference product.
A competitor could target one of several approaches:
- An equivalent tesamorelin formulation.
- A different concentration or reconstitution system.
- A distinct delivery device.
- A 505(b)(2) product supported by literature and bridging studies.
- A compounded or clinic-distributed product, although such products would not have the same approval and reimbursement position.
Are Paragraph IV challenges likely for tesamorelin?
Paragraph IV litigation risk is possible but not currently comparable to the risk surrounding large oral drugs with extensive generic manufacturing capacity.
A generic applicant would need to address:
- Peptide identity, purity, aggregation, and potency.
- Stability through reconstitution and storage.
- Bioequivalence or clinical bridging requirements.
- The specific vial, diluent, and administration process.
- Listed patents and any method-of-use claims.
- FDA requirements for a product used in a medically complex HIV population.
A Paragraph IV filing could still create material risk if the relevant patent estate is narrow or expired. The commercial opportunity for a challenger is constrained by the small patient pool, specialized distribution, and potential need for clinical or device-development work. That may delay entry even when the legal barrier is modest.
No broad, established wave of tesamorelin generic litigation has reshaped the U.S. market. The nearer-term threat is a carefully designed peptide competitor rather than a large number of conventional generic entrants.
What FDA safety issues affect tesamorelin demand?
The principal safety and monitoring issues are clinically important and commercially relevant:
- Elevated insulin-like growth factor 1.
- Glucose intolerance and possible diabetes risk.
- Fluid retention.
- Arthralgia and myalgia.
- Carpal tunnel syndrome.
- Injection-site reactions.
- Potential concern in patients with active malignancy.
- Contraindication in pregnancy because of potential fetal harm.
- Need for assessment of pituitary or hypothalamic disorders.
The label also limits use in patients with certain malignancies and requires clinical judgment where growth-hormone activity could be problematic.[1]
These requirements increase the cost of prescribing and can reduce persistence. They also create a barrier to indiscriminate off-label use, which supports the specialty-product positioning but limits volume expansion.
What licensing deals and commercial rights affect tesamorelin?
Theratechnologies has been the principal company associated with Egrifta commercialization in the United States. Historical development and commercialization arrangements involved other pharmaceutical companies, including EMD Serono, before Theratechnologies consolidated control of the product’s commercial strategy.[3]
The commercial-rights structure matters because tesamorelin revenue is concentrated in one company. There is no large network of competing branded licensees driving price competition. Theratechnologies controls pricing, market access, specialty-pharmacy relationships, and lifecycle-management decisions in its core market.
The company’s dependence on a small number of HIV products creates concentration risk. Strong Egrifta SV performance can support cash generation, but a reimbursement setback, safety signal, supply disruption, or competitor launch would have an outsized effect on corporate results.
What generic launch scenarios exist for tesamorelin?
Scenario 1: No near-term competitor
Egrifta SV retains specialty-market share, and revenue grows through patient identification, improved reimbursement execution, and continued treatment persistence. This is the most favorable outcome for Theratechnologies.
Scenario 2: 505(b)(2) or peptide competitor
A competitor launches a similar tesamorelin product with an alternative formulation, concentration, or delivery system. Price discounts and payer switching reduce net revenue, while Theratechnologies retains patients who value established supply and patient-support services.
Scenario 3: Formulation-led erosion
A competitor designs around product-specific claims and obtains approval without directly challenging every commercial feature of Egrifta SV. This would create gradual erosion rather than an immediate generic collapse.
Scenario 4: Off-label metabolic substitution
Physicians increasingly use GLP-1-based therapies or other weight-management approaches for HIV-associated adiposity. This would pressure demand without requiring a direct tesamorelin competitor.
How strong is the tesamorelin commercial position?
The commercial position is moderate. It is stronger than the size of the market might suggest because Egrifta SV has a focused indication, limited direct competition, and a specialized distribution model. It is weaker than that of a protected biologic with long-duration composition-of-matter patents.
| Strength |
Weakness |
| Defined unmet need in HIV-associated lipodystrophy |
Small eligible population |
| Limited direct FDA-approved competition |
Daily subcutaneous injection |
| Recurring treatment demand |
Monitoring and contraindications |
| Established Theratechnologies commercial infrastructure |
Dependence on a small product portfolio |
| Reformulated Egrifta SV product |
Exposure to reimbursement restrictions |
| High clinical specialization |
Potential competition from GLP-1 therapies and future peptides |
Geographic protection is also limited. The principal commercial opportunity is the United States, where Theratechnologies has built the strongest infrastructure. International sales are less significant and may face different reimbursement, approval, and patent conditions.
Key Takeaways
- Tesamorelin is marketed in the United States as Egrifta SV for excess abdominal fat in adults with HIV-associated lipodystrophy.
- The product is a specialty chronic therapy with recurring revenue but a limited addressable population.
- Theratechnologies’ financial exposure is meaningful because Egrifta SV is one of its core commercial products.
- Growth depends on diagnosis, payer approval, patient persistence, and specialty-pharmacy execution.
- GLP-1 therapies are the main indirect competitive threat, although they are not approved for tesamorelin’s specific indication.
- Tesamorelin should not be analyzed as a conventional monoclonal-antibody biologic subject to ordinary biosimilar competition.
- Future generic risk is more likely to arise through a peptide, formulation, or 505(b)(2) competitor than through a large conventional generic wave.
- The patent estate is less powerful than that of a recently launched innovative medicine, making formulation, manufacturing, regulatory, and commercial barriers important.
- The largest near-term risks are reimbursement pressure, declining treatment persistence, metabolic-therapy substitution, and a targeted peptide competitor.
FAQs
Is tesamorelin approved for weight loss?
No. Egrifta SV is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general obesity or cosmetic weight loss.[1]
Is Egrifta SV a biologic?
Tesamorelin is a synthetic peptide drug. It should not be evaluated under the same commercial and regulatory framework as a conventional monoclonal-antibody biologic.
Can a generic company make tesamorelin?
A competitor could pursue an abbreviated or 505(b)(2) pathway, subject to FDA requirements for peptide characterization, formulation, manufacturing, and clinical bridging. Patent and regulatory barriers would determine timing.
Does tesamorelin compete directly with Wegovy or Zepbound?
No. The products have different approved indications and mechanisms. They can compete indirectly for metabolic-treatment budgets and physician attention.
What is the biggest financial risk for Theratechnologies?
The largest risk is concentration in a small HIV specialty market. A reimbursement change, loss of treatment persistence, supply disruption, safety issue, or targeted competitor could materially affect company revenue.
References
- U.S. Food and Drug Administration. (2023). Egrifta SV (tesamorelin) prescribing information.
- U.S. Food and Drug Administration. (2018). FDA approves Egrifta SV for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
- Theratechnologies Inc. (2023). Annual report for the fiscal year ended November 30, 2023.
- Theratechnologies Inc. (2024). Management discussion and analysis for the fiscal year ended November 30, 2024.
- Theratechnologies Inc. (2024). Annual financial statements and management discussion and analysis.
- Falutz, J., et al. (2010). Metabolic effects of tesamorelin in HIV-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
